Respiratory

Smoking cessation: pharmacotherapy and behavioral counseling

Clinical Overview and When to Suspect Tobacco Dependence

— Ask about cigarettes, cigars, pipes, hookah, smokeless tobacco, and e-cigarettes/vaping

— Document pack-years: (packs/day) × (years smoked); ≥20 pack-years triggers lung cancer screening eligibility (ages 50–80, quit <15 years)

— Ask about use

— Advise to quit with clear, personalized message

— Assess readiness to quit

— Assist with pharmacotherapy + counseling

— Arrange follow-up within 1 week of quit date

— First cigarette within 30 minutes of waking (Fagerström indicator)

— >20 cigarettes/day

— Reports withdrawal (irritability, anxiety, insomnia, increased appetite, dysphoria) within hours of last use

Board pearl: USPSTF recommends behavioral interventions + FDA-approved pharmacotherapy for all adult smokers (Grade A) and behavioral interventions alone for pregnant smokers (Grade A); pharmacotherapy in pregnancy is Grade I (insufficient evidence) — counseling first.

Step 3 management: Even a brief 3-minute physician advice intervention increases quit rates — never skip the "Advise" step, even in a packed clinic. Combining counseling with pharmacotherapy roughly doubles quit rates compared to either alone.

Tobacco use disorder is the leading preventable cause of death in the US (~480,000 deaths/year) and a modifiable risk factor for nearly every organ system disease

Screen every adult at every visit for tobacco use — USPSTF Grade A recommendation

The 5 A's framework structures every encounter:

For patients not ready to quit, use the 5 R's motivational approach: Relevance, Risks, Rewards, Roadblocks, Repetition

Suspect heavy nicotine dependence when patient smokes:

Comorbid conditions strongly linked to ongoing smoking: COPD, CAD, PAD, bladder/lung/head-and-neck cancers, depression, schizophrenia, substance use disorders, pregnancy complications

Presentation Patterns and Key History

— Post-MI, post-stroke, new cancer diagnosis, pregnancy, new asthma/COPD diagnosis, hospitalization

— Quit rates after MI approach 50% if cessation initiated before discharge

— Quantity: cigarettes/day, years smoked → pack-years

— Dependence severity: time to first cigarette, prior withdrawal symptoms

— Prior quit attempts: number, methods used, longest abstinence, what triggered relapse

— Triggers: stress, alcohol, coffee, social settings, specific people

— Motivation/readiness: Stages of Change (precontemplation → contemplation → preparation → action → maintenance)

— Household smokers (relapse risk doubles)

— Mental health: depression, anxiety, bipolar, schizophrenia — high prevalence, must be screened

— Substance use: alcohol and cannabis co-use are major relapse drivers

— Which agent, dose, duration, side effects, reason for stopping

— Many patients underdose NRT or stop varenicline early due to nausea

Key distinction: Contemplation = thinking about quitting in next 6 months; Preparation = planning to quit within 30 days — only preparation-stage patients should be offered a quit date and pharmacotherapy initiation. Precontemplators get the 5 R's, not a prescription.

Board pearl: A history of seizure disorder or eating disorder is a contraindication to bupropion; a history of serious psychiatric illness is no longer a contraindication to varenicline (2016 EAGLES trial removed the black box warning).

Smokers rarely present for cessation — opportunity arises during routine visits, acute illness (MI, COPD exacerbation, pneumonia), or preoperative evaluation

Teachable moments dramatically increase quit success:

Key history elements to elicit:

Ask about prior pharmacotherapy specifically:

Explore patient-stated reasons to quit: health, family, cost (~$3000/year for pack-a-day), pregnancy, smell, control

Physical Exam Findings and Risk Assessment

— Skin: premature wrinkling ("smoker's face"), yellow-stained fingers/nails, delayed wound healing

— Oral: halitosis, tobacco staining of teeth, gingival recession, leukoplakia, erythroplakia (premalignant)

— Eyes: conjunctival injection; increased risk of macular degeneration and cataracts

— Pulmonary: prolonged expiratory phase, wheezing, decreased breath sounds, hyperresonance, clubbing (suggests lung cancer or bronchiectasis, not COPD alone)

— Cardiovascular: diminished peripheral pulses, bruits, AAA on abdominal exam

— Voice: hoarseness (laryngeal irritation or malignancy)

— Exhaled CO >6–10 ppm suggests recent smoking (half-life ~4 hours)

— Urine or salivary cotinine (nicotine metabolite, half-life ~16 hours) — useful for verification in pregnancy, clinical trials, or insurance contexts

— Cotinine is also elevated by NRT, so it cannot distinguish smoking from NRT use

Step 3 management: In a preoperative visit, document smoking status, advise cessation, and offer NRT for the perioperative period — even 4 weeks of preoperative abstinence reduces wound complications and pulmonary morbidity. Smoking the morning of surgery is not a contraindication to proceeding but should be documented.

Board pearl: AAA screening with one-time abdominal ultrasound is recommended for men ages 65–75 who have ever smoked (USPSTF Grade B).

Smoking has few pathognomonic exam findings but produces a constellation of clues:

Vital signs during withdrawal: mild tachycardia, hypertension, restlessness — usually peaks 24–72 hours, resolves over 2–4 weeks

Cravings persist much longer (months) even after physical withdrawal resolves

Objective biomarkers when verification needed:

Calculate cardiovascular risk (ASCVD calculator) — smoking is a major modifiable input; quitting drops CV risk by ~50% within 1 year

Diagnostic Workup — Assessing Dependence and Comorbidities

— Heaviest weight on time to first cigarette (<5 min = 3 points) and cigarettes/day

— Score ≥6 indicates high dependence → favors combination pharmacotherapy and varenicline

— Depression screen (PHQ-9) — untreated depression predicts relapse

— Anxiety, PTSD, bipolar — affect drug choice

— Alcohol use (AUDIT-C) — concurrent treatment improves outcomes

— Pregnancy test in women of reproductive age before starting pharmacotherapy

— CBC — smokers often have elevated Hgb/Hct from chronic hypoxemia

— Lipid panel, A1c, BP — for cardiovascular risk stratification

— LFTs if starting bupropion in heavy alcohol user

— Renal function if considering varenicline (dose adjust if CrCl <30)

— Adults 50–80 years old

— ≥20 pack-year history

— Current smoker or quit within 15 years

— Shared decision-making required; stop screening once patient has quit for 15 years or develops a life-limiting comorbidity

CCS pearl: In a hospitalized smoker, order NRT on admission to prevent withdrawal-driven discharge against medical advice; document smoking status, provide brief counseling, and arrange outpatient follow-up — these are Joint Commission tobacco performance measures.

Key distinction: Cotinine confirms exposure; exhaled CO confirms recent active combustion — only exhaled CO distinguishes smoking from NRT.

Tobacco use disorder is a clinical diagnosis — DSM-5 criteria require ≥2 of 11 symptoms (tolerance, withdrawal, use larger amounts than intended, unsuccessful quit attempts, craving, social/occupational impairment, etc.) over 12 months

Fagerström Test for Nicotine Dependence (FTND) quantifies severity (0–10):

Screen for comorbidities that modify therapy choice:

Labs are not routinely needed to diagnose tobacco use disorder, but consider:

Lung cancer screening with low-dose CT chest annually for:

Spirometry if dyspnea, chronic cough, or sputum production — diagnose COPD early to leverage as motivation

Diagnostic Workup — Identifying Relapse Risk and Tailoring Strategy

— High-risk features: prior relapses, heavy daily use (>1 ppd), high FTND, mental illness, substance use, partner who smokes, high-stress occupation, low social support

— High-risk patients benefit from combination pharmacotherapy + intensive counseling (4+ sessions, ≥10 minutes each)

— Time, location, mood, activity, craving intensity for each cigarette

— Reveals "automatic" cigarettes (with coffee, after meals, while driving) vs. "emotional" cigarettes (stress, boredom)

— Stages of Change (Transtheoretical Model) — matches intervention to readiness

— Motivational interviewing — open questions, affirmations, reflective listening, summaries (OARS); rolling with resistance rather than confrontation

— Cognitive Behavioral Therapy (CBT) — identifies triggers, builds coping skills, addresses cognitive distortions ("I can't handle stress without smoking")

— 1-800-QUIT-NOW (state quitlines) — free, evidence-based, available in multiple languages

— SmokefreeTXT, smokefree.gov apps

— Group programs (American Lung Association Freedom From Smoking)

— In-person individual counseling (covered without copay under ACA preventive services)

— Remove all tobacco, ashtrays, lighters from home/car/work

— Inform family and coworkers

— Identify substitute behaviors (gum, walks, water)

— Anticipate high-risk situations and plan responses

Board pearl: Intensity matters — more counseling time (and more sessions) produces dose-response improvement in quit rates. Person-to-person counseling >4 sessions is the highest-yield behavioral intervention.

Step 3 management: Offer both pharmacotherapy and counseling at the same visit — they are additive, not redundant. Refusing one does not preclude the other.

After confirming dependence, stratify relapse risk to guide intensity of intervention:

Identify trigger patterns through a smoking diary (1 week pre-quit):

Behavioral assessment tools Step 3 expects you to recognize:

Counseling resources to mobilize:

Set a quit date within 2 weeks — long enough to prepare, short enough to maintain momentum

Pre-quit preparation:

Risk Stratification and First-Line Management Logic

— Varenicline (Chantix) — highest single-agent efficacy

— Nicotine replacement therapy (NRT) — patch, gum, lozenge, inhaler, nasal spray

— Bupropion SR (Zyban)

— EAGLES trial (2016) showed varenicline superior to NRT and bupropion, with no excess neuropsychiatric events — FDA removed the black box warning

— Long-acting patch + short-acting NRT (gum or lozenge for breakthrough cravings) — strong evidence

— Varenicline + NRT patch — emerging evidence of superiority in heavy smokers

— Varenicline + bupropion — option for very heavy smokers or those who failed monotherapy

— Depression history → bupropion (treats both) or varenicline

— Seizure or eating disorder → avoid bupropion

— Severe renal impairment → reduce varenicline dose

— Pregnancy → behavioral counseling first; NRT if needed after shared decision-making

— Cardiovascular disease → all three agents are safe; do not withhold therapy

— Cost/insurance → NRT often cheapest and OTC

Key distinction: Quit rates at 6 months — varenicline ~25–35%, combination NRT ~25–30%, bupropion ~20%, single NRT ~15–20%, behavioral counseling alone ~10–15%, unaided ~3–5%.

Board pearl: Never tell a patient "just use willpower" — that's the lowest-efficacy strategy and a wrong answer on Step 3.

Three first-line FDA-approved pharmacotherapies for smoking cessation, all roughly doubling quit rates vs. placebo:

2020 USPSTF + 2020 ATS guidelines now favor varenicline as first-line for most adults, including those with stable cardiovascular and psychiatric disease

Combination therapy is more effective than monotherapy and is recommended for moderate-to-severe dependence:

Treatment duration: standard course is 12 weeks; extending to 24 weeks improves long-term abstinence in responders

Choosing an agent — patient-specific factors:

Initiate pharmacotherapy 1–2 weeks before quit date (varenicline, bupropion) or on the quit date (NRT) — or use flexible quit-date approaches (gradual reduction with NRT)

Pharmacotherapy — First-Line Drug Regimens in Detail

— Reduces cravings (agonist effect) and blocks reward from smoking (antagonist effect)

— Dosing: 0.5 mg daily ×3 days → 0.5 mg BID ×4 days → 1 mg BID for 11+ weeks

— Start 1 week before quit date; take with food and full glass of water

— Side effects: nausea (30%), vivid/abnormal dreams, insomnia, headache, constipation

— Renal dosing: CrCl <30 → max 0.5 mg BID

— Monitor mood; report new agitation, depression, suicidal ideation (rare)

— Safe in stable CVD (CHRYSALIS, EAGLES-CV substudies)

— Patch (long-acting): 21 mg/day for >10 cig/day × 6 weeks → 14 mg × 2 weeks → 7 mg × 2 weeks; rotate sites; remove at night if vivid dreams/insomnia

— Gum: 2 mg if first cigarette >30 min after waking, 4 mg if <30 min; "chew and park" technique against buccal mucosa; avoid acidic beverages 15 min before/after

— Lozenge: same dosing logic as gum; let dissolve, do not chew

— Inhaler and nasal spray: prescription only; useful for hand-to-mouth behavior or rapid craving relief

— Side effects: local irritation, hiccups (lozenge/gum), vivid dreams (patch), nasal irritation (spray)

— Combination NRT: patch + PRN gum/lozenge is superior to monotherapy and is now considered first-line

— Dosing: 150 mg daily ×3 days → 150 mg BID for 7–12 weeks

— Start 1 week before quit date

— Contraindications: seizure disorder, eating disorder (bulimia/anorexia), abrupt alcohol/benzo withdrawal, MAOI use within 14 days

— Side effects: insomnia (give second dose before 5 PM), dry mouth, agitation, lowered seizure threshold

Step 3 management: A 1-ppd smoker who failed patch monotherapy should be escalated to combination NRT (patch + lozenge) or varenicline, not retried on the same regimen.

Board pearl: Varenicline + nicotine patch outperforms either alone in heavy smokers — and is a favorite Step 3 answer for "failed monotherapy."

Varenicline (Chantix) — partial α4β2 nicotinic acetylcholine receptor agonist

Nicotine Replacement Therapy (NRT) — replaces nicotine without combustion toxins

Bupropion SR (Zyban) — atypical antidepressant; inhibits dopamine/norepinephrine reuptake and antagonizes nicotinic receptors

Expanded Pharmacology — Second-Line, Adjuncts, and What to Avoid

— Nortriptyline — tricyclic; 75–100 mg/day; useful in patients with depression who failed first-line

— Clonidine — α2-agonist; reduces withdrawal; oral 0.1–0.3 mg BID or transdermal patch; side effects: sedation, hypotension, rebound HTN

— Both require specialist comfort and are uncommon on boards as first-line answers

— Not FDA-approved as a cessation aid

— Some RCT evidence (UK Cochrane review) shows modest efficacy, but US guidelines (ATS, USPSTF) recommend FDA-approved pharmacotherapy over e-cigarettes

— Risks include EVALI (e-cigarette/vaping-associated lung injury, especially with THC/vitamin E acetate), continued nicotine dependence, dual use

— If a patient has switched completely to e-cigarettes, encourage transition off them; do not initiate e-cigarettes for non-vaping smokers

— Smoking induces CYP1A2 → cessation increases levels of theophylline, clozapine, olanzapine, caffeine, warfarin — monitor and dose-adjust

— Bupropion is a CYP2D6 inhibitor — affects metoclopramide, tamoxifen, many antidepressants

— Varenicline has minimal drug interactions (renally cleared, no CYP metabolism) — advantage in polypharmacy

— Bupropion: seizures, eating disorders, MAOIs

— Varenicline: severe renal impairment (dose-adjust), caution with operating heavy machinery if sleep effects

— NRT: relative caution in acute MI within 2 weeks, unstable angina, serious arrhythmia — but generally smoking is far more dangerous than NRT; use NRT in stable CVD

Board pearl: A patient on clozapine who quits smoking can develop toxicity (sedation, seizures) within 1–2 weeks — proactively reduce clozapine dose by ~25% at the quit date and monitor levels.

Key distinction: E-cigarettes ≠ FDA-approved cessation therapy — on Step 3, recommend NRT, varenicline, or bupropion instead.

Second-line agents (off-label but evidence-supported, used when first-line fails or is contraindicated):

Cytisine — partial nicotinic agonist (varenicline analog); widely used internationally, not yet FDA-approved in US as of current guidelines; mentioned for awareness only

E-cigarettes for cessation:

Drug interactions to remember:

Contraindications and cautions summary:

Special Populations — Elderly and Renal/Hepatic Impairment

— Never too late to quit — even quitting at age 65 adds 1.4–3.7 years of life expectancy

— Quit rates are higher in older adults (more disease motivation, more stable lives)

— All first-line agents are safe; start at standard doses

— Watch for polypharmacy interactions: warfarin (smoking cessation may increase INR), theophylline, antipsychotics

— Bupropion: lower seizure threshold with age, polypharmacy; consider starting at 100 mg SR daily and titrating

— Falls risk with insomnia/dizziness from any agent

— NRT patch is often best tolerated; gum may be difficult with dentures — use lozenge instead

— Varenicline: CrCl 30–50 → no adjustment; CrCl <30 → max 0.5 mg BID; ESRD on hemodialysis → max 0.5 mg daily

— Bupropion: use with caution in CKD; reduce dose/frequency in severe impairment; metabolites accumulate

— NRT: generally safe; dose by smoking pattern, not renal function

— Bupropion: severe hepatic cirrhosis → max 150 mg every other day

— Varenicline: no adjustment needed (renally cleared)

— NRT: no adjustment needed

— Practically: NRT and varenicline are the safer choices in liver disease

— All three agents are safe in stable CVD (post-MI >2 weeks, stable angina, controlled HF)

— NRT package warnings about recent MI exist but are outdated — smoking risk far exceeds NRT risk

— Varenicline: large meta-analyses show no significant excess CV events

— Varenicline is safe in stable depression, anxiety, bipolar, schizophrenia (EAGLES trial)

— Bupropion is particularly useful if comorbid MDD — single agent for both

— Always screen for and monitor mood changes

Step 3 management: In a 72-year-old smoker with stage 3b CKD (CrCl 35) and CAD, varenicline at standard dose + behavioral counseling is appropriate first-line therapy — do not withhold treatment because of age or comorbidities.

Older adults (≥65):

Renal impairment:

Hepatic impairment:

Cardiovascular disease:

Mental health comorbidity:

Special Populations — Pregnancy, Adolescents, and Behavioral Health

— Smoking in pregnancy → preterm birth, IUGR, placental abruption, placenta previa, SIDS, stillbirth, congenital anomalies (orofacial clefts)

— First-line: intensive behavioral counseling (USPSTF Grade A) — every pregnant smoker, every visit

— Pharmacotherapy in pregnancy: USPSTF Grade I (insufficient evidence) — but ACOG supports NRT after shared decision-making if counseling alone fails

— If using NRT in pregnancy: intermittent (gum, lozenge) preferred over patch to minimize fetal exposure, or remove patch at night

— Avoid bupropion and varenicline in pregnancy unless benefits clearly outweigh risks (limited safety data)

— Postpartum relapse rates ~60–80% — proactive relapse prevention counseling is essential

— Nicotine enters breast milk; smoking is still worse than NRT

— Smoke immediately after feeding (not before) and away from infant

— NRT compatible with breastfeeding

— USPSTF (2020): counseling/interventions to prevent initiation in school-age children and adolescents (Grade B)

— For adolescent smokers/vapers: behavioral counseling recommended; insufficient evidence for pharmacotherapy (Grade I) — but clinically, NRT is often used in heavily dependent adolescents

— Address vaping epidemic — ask all adolescents about e-cigarette use; warn about nicotine addiction and EVALI

— Smoking rates 2–4× general population; smoking accounts for much of the mortality gap in schizophrenia

— Varenicline and bupropion are safe and effective; do not withhold based on diagnosis

— Address with the psychiatrist; monitor for mood changes

— Treat tobacco concurrently with other SUDs — improves outcomes for both

— Smoking cessation does not worsen recovery from alcohol/opioid use disorders

Board pearl: In pregnancy, the answer is almost always "intensive behavioral counseling" before pharmacotherapy. Pharmacotherapy is a shared-decision second step.

Key distinction: Pregnant adolescent who smokes → counseling first, the same as any pregnant patient — pregnancy trumps the adolescent algorithm.

Pregnancy:

Breastfeeding:

Adolescents:

Patients with serious mental illness:

Substance use disorders:

Complications and Adverse Outcomes

— Cardiovascular: CAD, MI, stroke, PAD, AAA, sudden cardiac death — smoking is the strongest modifiable CV risk factor

— Pulmonary: COPD, lung cancer, increased pneumonia/TB risk, accelerated FEV1 decline

— Oncologic: lung, larynx, oropharynx, esophagus, pancreas, bladder, kidney, cervix, AML

— Reproductive: infertility, ectopic pregnancy, early menopause, ED

— Bone: osteoporosis, delayed fracture healing

— Wound healing: surgical site complications, flap failure

— Ophthalmologic: macular degeneration, cataracts

— Dental: periodontitis, tooth loss, oral cancers

— 20 minutes: BP and HR normalize

— 12 hours: CO levels normalize

— 2 weeks–3 months: lung function improves, circulation improves

— 1 year: CHD risk halved

— 5 years: stroke risk approaches non-smoker

— 10 years: lung cancer death rate halved

— 15 years: CHD risk equals non-smoker

— Varenicline: nausea (take with food), vivid dreams, rare neuropsychiatric symptoms, very rare seizures/CV events

— Bupropion: seizures (~0.1%), insomnia, agitation, hypertension, suicidality black box (general antidepressant class warning)

— NRT: skin reactions (patch), oral irritation (gum/lozenge), insomnia (overnight patch), nicotine toxicity if combined with continued smoking (nausea, palpitations, headache)

Step 3 management: A patient on varenicline who develops new depression or suicidal ideation → discontinue varenicline, assess safety, and transition to NRT or bupropion (if no contraindication). Document and report adverse event.

Board pearl: Lapse ≠ relapse. A single cigarette is a lapse; encourage the patient to continue medication and counseling rather than abandoning the quit attempt.

Complications of continued smoking (motivational counseling material):

Benefits of quitting (timeline patients should know):

Adverse effects of pharmacotherapy:

Post-cessation weight gain: average 4–5 kg over first year — reassure patients health benefits vastly outweigh weight risks; preemptively counsel diet/exercise

Withdrawal syndrome: irritability, anxiety, depressed mood, insomnia, restlessness, increased appetite, difficulty concentrating, cravings — peaks 24–72 hours, mostly resolves over 2–4 weeks

When to Escalate Care — Referral and Intensive Intervention

— Multiple failed quit attempts despite combination pharmacotherapy and counseling → tobacco treatment specialist or pulmonology cessation clinic

— Severe psychiatric comorbidity complicating cessation → psychiatry co-management

— Concurrent substance use disorder → addiction medicine

— Pregnant smoker unable to quit with counseling → maternal-fetal medicine + shared decision on pharmacotherapy

— Adolescent with severe nicotine dependence including high-dose vaping → adolescent medicine

— Every hospitalized smoker should receive cessation intervention — Joint Commission core measure

— Initiate NRT on admission to prevent withdrawal

— Brief counseling during stay

— Arrange post-discharge follow-up within 1 week plus quitline referral — this transition is the single biggest predictor of long-term abstinence

— Hospitalization is a teachable moment with quit rates 2–3× higher than outpatient initiation

— Recommend cessation at least 4 weeks preoperatively to reduce wound and pulmonary complications

— Offer NRT through perioperative period (do not withhold day-of-surgery NRT)

— Document smoking status in pre-op note

— Initiate cessation before discharge post-MI, post-CABG, post-PCI, post-stroke

— Cardiac rehab programs should include cessation counseling

— Pulmonary rehab similarly for COPD

— Continued smoking worsens treatment response, increases recurrence, increases second primaries — cessation improves cancer outcomes

— Refer to oncology-integrated cessation programs

CCS pearl: On a CCS case with a hospitalized smoker, the order set should include: nicotine patch (with PRN lozenge), smoking cessation counseling consult, and outpatient follow-up appointment within 7 days of discharge. Missing these is a documented quality gap.

Step 3 management: Quitlines (1-800-QUIT-NOW) are an evidence-based, free, scalable referral — appropriate for nearly every smoker and a high-yield Step 3 answer.

Most smoking cessation occurs in primary care — escalation is reserved for complex or refractory cases

Indications for specialty referral:

Inpatient management of hospitalized smokers:

Surgical patients:

Cardiac and stroke patients:

Cancer patients:

Key Differentials — Same-Category Causes (Other Tobacco/Nicotine Use)

— Cigarettes — most common; full guideline applies

— Cigars and cigarillos — often used without inhalation but still cause oral, laryngeal, esophageal cancers; many young adults use as "less harmful"

— Pipes — similar oral cancer risk

— Hookah/waterpipe — common misconception that water filters toxins; a single session ≈ smoking 100 cigarettes in CO and tar exposure

— Smokeless tobacco (chew, dip, snus) — causes oral cancer, periodontal disease, hypertension; NRT, varenicline, and bupropion all effective

— E-cigarettes/vaping — nicotine salts deliver high doses; addiction in adolescents; EVALI risk especially with THC/vitamin E acetate

— Heated tobacco products (IQOS) — reduced but not eliminated harm

— Inadequate pharmacotherapy dose or duration

— Untreated comorbid depression/anxiety

— Inadequate behavioral support

— Household smoker or high-stress environment

— Concurrent alcohol/cannabis use (relapse triggers)

Key distinction: Nicotine ≠ tobacco. Nicotine causes dependence and cardiovascular effects; combustion causes the cancers and COPD. This is why NRT is far safer than smoking.

Board pearl: A patient who "only smokes cigars socially" or "only vapes" still has tobacco use disorder by DSM-5 criteria if dependence features are present — apply the full 5 A's framework.

Tobacco use comes in many forms — all addictive, all warrant cessation intervention:

Polytobacco use is common — ask specifically about each product; intervene on all

Dual use of cigarettes and e-cigarettes is associated with worse health outcomes than either alone and lower quit rates — push toward complete cessation, not switching

Nicotine pouches (Zyn, etc.) — smokeless, tobacco-free oral nicotine; rapidly growing use, especially in young adults; long-term effects unknown but maintain dependence

Nicotine itself is the addictive component but not the carcinogen — the combustion products and tar drive cancer; this distinction supports NRT safety

Differential of "wants to quit but can't":

Key Differentials — Other-Category Causes of Similar Symptoms

— Chronic cough: smoking is #1 cause, but consider postnasal drip (UACS), GERD, asthma/cough-variant asthma, ACE inhibitor cough, bronchiectasis, lung cancer, TB

— Dyspnea: COPD vs. heart failure, asthma, ILD, anemia, deconditioning, PE

— Hemoptysis in a smoker: lung cancer until proven otherwise, plus bronchitis, PE, bronchiectasis, TB, pulmonary AVM

— Hoarseness >2 weeks in a smoker: refer to ENT for laryngeal cancer workup with laryngoscopy

— Weight loss in a smoker: screen aggressively for lung, GI, head/neck malignancy

— Nicotine withdrawal peaks 24–72 hours, resolves over 2–4 weeks

— Persistent depression/anxiety beyond 4 weeks → likely a primary mood/anxiety disorder unmasked by cessation, not withdrawal — treat appropriately

— Bupropion (give second dose before 5 PM)

— Varenicline (vivid dreams)

— Nicotine patch overnight (remove at bedtime)

— Underlying anxiety or OSA — screen and treat

Step 3 management: A 60-year-old smoker with a 3-week cough and 10-lb weight loss → order chest CT, not just chest x-ray; consider sputum cytology and referral. Don't attribute new symptoms to "just smoker's cough."

Board pearl: In a smoker with new-onset hoarseness or dysphagia lasting >2 weeks, the wrong answer is to wait — laryngoscopy/endoscopy is the right next step.

Smoking-related symptoms overlap with other diagnoses; rule these in/out:

Withdrawal vs. other anxiety/mood disorders:

Insomnia after starting therapy:

Nausea on varenicline: most common side effect; usually improves over 1–2 weeks; take with food and full glass of water; can reduce dose if persistent

"Brain fog" early in cessation: part of withdrawal; resolves over weeks; reassure

New cough or chest pain post-cessation: mucociliary clearance returns and patients cough up accumulated secretions — usually benign but evaluate red flags (hemoptysis, focal findings, weight loss)

Resumed smoking despite NRT: check for underdosing (low patch strength, infrequent gum use) — escalate dose or add second NRT modality

Secondary Prevention / Discharge Plan / Long-Term Maintenance

— Pharmacotherapy prescription with refills sufficient for full 12-week course (consider 24 weeks for high-risk)

— Written quit plan: quit date, triggers, coping strategies, support contacts

— Quitline referral (1-800-QUIT-NOW) with active warm handoff if possible

— Follow-up appointment within 1 week of quit date, then at 1 month, 3 months, 6 months, 12 months

— Behavioral counseling referral — group, individual, telephonic, or app-based

— Identify and avoid high-risk situations (alcohol use is the #1 trigger)

— Develop coping skills: deep breathing, distraction, delay (cravings peak at 3–5 min)

— "NOT" strategy for cravings: Negotiate (delay), Out (leave situation), Time out (5-min wait)

— Build a non-smoking identity ("I'm a non-smoker" rather than "I'm trying to quit")

— Engage family/social support; address household smokers

— Anticipate 4–5 kg gain; reassure benefits outweigh

— Encourage physical activity (also reduces cravings)

— Healthy snack substitution; avoid restrictive dieting in early cessation (depletes self-regulation resources)

— A single cigarette is not failure; reset the quit date, continue medication, identify the trigger

— Many smokers require 5–7 quit attempts before sustained abstinence

— Tobacco cessation counseling and FDA-approved medications are covered without cost-sharing under ACA preventive services

— Verify Medicaid/Medicare coverage of varenicline (Medicare Part D)

Step 3 management: Combination NRT can be continued safely beyond 12 weeks in patients at high relapse risk — extended therapy is appropriate and evidence-based, not "drug dependence."

Board pearl: Document quit status at every subsequent visit — relapse rates are highest in months 1–3, but late relapses occur for years.

Long-term maintenance is where most quit attempts fail — relapse risk highest in first 3 months, persists for years

Discharge or visit-end plan should include:

Relapse prevention strategies:

Manage post-cessation weight gain:

Address lapses immediately:

Update insurance/ACA preventive benefits:

Follow-Up, Monitoring, and Rehab/Counseling

— Week 1 — phone or visit; assess withdrawal, side effects, adherence, lapses

— Week 2–4 — medication tolerance, mood, weight, trigger management

— Month 2–3 — sustained abstinence assessment; consider extending pharmacotherapy

— Month 6, 12 — long-term verification; address late relapses

— Mood screen (PHQ-9) at each visit early in cessation; new depression can emerge

— Blood pressure and weight — both often rise

— For varenicline: nausea, sleep changes, mood changes, rare CV symptoms

— For bupropion: seizure risk factors, sleep, agitation, BP

— For NRT: skin reactions, oral irritation, signs of overdosing (nausea, palpitations) if patient lapsed and smoked while patched

— Adjust doses of CYP1A2 substrates (theophylline, clozapine, olanzapine, warfarin) after cessation

— Exhaled CO <6 ppm supports abstinence

— Cotinine if not on NRT

— Cardiac rehab — mandatory cessation component post-MI/CABG/PCI

— Pulmonary rehab — for COPD; cessation is essential to slow FEV1 decline

— Cancer survivorship programs — cessation improves outcomes

— Behavioral counseling modalities: in-person individual, group, telephonic (quitline), text messaging (SmokefreeTXT), apps

— CBT — addresses cognitive distortions; motivational interviewing — builds intrinsic motivation; contingency management — financial incentives improve quit rates

Board pearl: At least 4 counseling sessions of ≥10 minutes each significantly outperforms briefer interventions — dose-response is real.

Step 3 management: A patient 9 months post-quit asking about stopping varenicline → if stable, can discontinue; if recent stress or cravings, consider continuing through 12 months — extended therapy is safe and effective.

Follow-up cadence after quit date:

Monitoring parameters:

Objective verification (when needed for high-stakes contexts):

Rehab and counseling integration:

Recheck lung cancer screening eligibility annually — patient who has quit <15 years still qualifies for LDCT if age and pack-year criteria met

Re-engage every visit — even patients in maintenance phase benefit from acknowledgment and reinforcement

Ethical, Legal, and Patient Safety Considerations

— Counsel every visit, but respect autonomy — patient has right to decline; do not shame or moralize

— Use motivational interviewing rather than confrontation; "rolling with resistance"

— Document advice given and patient response

— Discuss benefits, side effects, alternatives, and option of no treatment

— Specifically discuss neuropsychiatric monitoring with varenicline and bupropion, even after the black box removal — patients should know to report mood changes

— In pregnancy, document shared decision-making if pharmacotherapy is used (Grade I evidence)

— Confidentiality in adolescent smoking/vaping disclosure — most states allow minors to consent to substance use treatment; clarify your state's rules

— Be cautious about disclosing to parents without adolescent consent unless safety requires it

— Counseling to prevent initiation is USPSTF Grade B for all school-age children

— Smoking in pregnancy is not a reportable child welfare issue per se, but maternal substance use of illicit drugs in pregnancy has state-specific reporting rules

— Smoking near children in cars — some states have laws prohibiting; counsel on secondhand smoke harm regardless

— Foster care/custody cases — smoking exposure may be a documented factor

— Hospital discharge without pharmacotherapy or follow-up → relapse rate >70%

— Always arrange post-discharge plan: medication continuation, quitline referral, follow-up within 7 days

— Post-surgical patients lose continuity — explicit handoff to primary care

— Smoking rates higher in low-income, rural, LGBTQ+, mental illness, and certain racial/ethnic minority populations — target interventions equitably

— Tobacco surcharges on insurance can discourage disclosure — be aware and document honestly without weaponizing

— ACA covers cessation services without cost-sharing — leverage this

— Many states/employers offer cessation benefits

— Smoke-free workplace laws reduce population smoking rates

Step 3 management: A patient in maintenance phase asks you to omit smoking history from insurance application — decline; document honestly. Falsifying records is unethical and illegal. Offer to advocate through legitimate channels (cessation documentation, post-quit reclassification after 12 months tobacco-free).

Board pearl: Counseling is not contingent on patient readiness — even precontemplators get brief advice and 5 R's. Skipping the conversation is the wrong answer.

Autonomy and respect:

Informed consent for pharmacotherapy:

Pediatric/adolescent considerations:

Mandatory reporting and special contexts:

Transitions of care — high-risk for relapse:

Health systems and equity:

Workplace and public health:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: When a Step 3 stem describes a heavily dependent smoker who has failed monotherapy, the answer is almost always combination therapy (varenicline + NRT, or patch + lozenge) plus intensive behavioral counseling, not switching to a single different agent at the same dose.

Screening: USPSTF Grade A — screen all adults for tobacco use; offer behavioral + pharmacotherapy to all smokers

5 A's = Ask, Advise, Assess, Assist, Arrange

5 R's (for unwilling quitters) = Relevance, Risks, Rewards, Roadblocks, Repetition

First-line meds: varenicline, NRT (patch + gum/lozenge), bupropion SR

Most effective monotherapy: varenicline

Most effective combination: varenicline + NRT, or combination NRT (patch + short-acting)

Quit rates roughly double with any first-line pharmacotherapy vs. placebo

Counseling + pharmacotherapy > either alone

Pregnancy: behavioral counseling first; pharmacotherapy is Grade I — shared decision

Bupropion contraindications: seizure disorder, eating disorder, MAOI use, abrupt alcohol/benzo withdrawal

Varenicline renal dosing: CrCl <30 → max 0.5 mg BID

EAGLES trial (2016): varenicline superior, no excess neuropsychiatric events → black box removed

Smoking induces CYP1A2 → cessation increases theophylline, clozapine, olanzapine, warfarin levels

Lung cancer screening (LDCT): ages 50–80, ≥20 pack-years, current or quit <15 yr

AAA screening: men 65–75 who ever smoked, one-time ultrasound

CV risk drops ~50% within 1 year of quitting; reaches non-smoker by 15 years

Lung cancer mortality halved at 10 years post-quit

Quit attempts often required: 5–7 before sustained abstinence

Post-cessation weight gain: ~4–5 kg average

Withdrawal peaks 24–72 hours, resolves 2–4 weeks; cravings persist months

Quitline: 1-800-QUIT-NOW (free, evidence-based)

ACA preventive coverage: tobacco cessation counseling + FDA-approved meds without cost-sharing

Joint Commission: tobacco screening, cessation counseling, and discharge planning are inpatient core measures

Hospitalization = teachable moment — initiate cessation pre-discharge with 1-week follow-up

Lapse ≠ relapse — continue medication, restart quit plan

E-cigarettes: NOT FDA-approved for cessation; recommend FDA-approved options instead

Smokeless tobacco: pharmacotherapy still effective; address with same algorithm

Board Question Stem Patterns

— Answer: 5 R's motivational counseling, not pharmacotherapy

— Wrong answers: "respect autonomy and do not discuss," prescribing varenicline now

— Answer: varenicline + behavioral counseling, or combination NRT + counseling

— Wrong: NRT patch alone, willpower, e-cigarettes

— Answer: intensive behavioral counseling

— If counseling fails → NRT after shared decision; avoid varenicline/bupropion

— Answer: initiate cessation before discharge — NRT or varenicline + counseling, follow-up in 1 week

— Wrong: "wait until outpatient cardiology visit"

— Avoid bupropion (seizure risk in eating disorders)

— Choose varenicline or combination NRT

— Varenicline 0.5 mg BID (renal dose)

— Anticipate clozapine level increase — reduce dose 25%, monitor levels and for toxicity

— Behavioral counseling first (Grade B); pharmacotherapy evidence insufficient (Grade I); clinically NRT may be considered

— Varenicline is safe post-EAGLES; or bupropion (treats both); monitor mood

— Likely nicotine withdrawal → nicotine patch + PRN lozenge, counseling, address AMA risk

— Reframe as lapse, not relapse; identify trigger; continue/restart pharmacotherapy; reinforce coping

— Recommend FDA-approved pharmacotherapy instead; note EVALI risk and unclear long-term safety

— Annual LDCT for lung cancer screening; one-time AAA ultrasound

Step 3 management: When the stem emphasizes transition of care (hospital discharge, postpartum, post-surgical), the right answer almost always includes pharmacotherapy continuation + follow-up appointment within 1 week + counseling referral — all three.

"Most appropriate next step" in a smoker presenting for routine visit who isn't ready to quit:

"Most effective therapy" for moderately dependent smoker ready to quit:

Pregnant smoker, 12 weeks gestation, smokes 10 cig/day:

Post-MI smoker about to be discharged:

Patient with bulimia nervosa wants to quit:

Patient with CKD stage 4 (CrCl 25):

Patient on clozapine quits smoking:

Adolescent vaping daily, wants help:

Smoker with depression history, prior SI:

Hospitalized smoker, day 2 of admission, irritable and demanding to leave:

Patient quit 6 months ago, now reports lapse last weekend:

Patient asks if e-cigarettes are a good way to quit:

65-year-old man, 40 pack-year smoker, quit 5 years ago, asymptomatic:

Quitline question: correct answer often "refer to 1-800-QUIT-NOW" — free, accessible, evidence-based

One-Line Recap

Tobacco cessation is the single highest-impact preventive intervention in medicine: at every visit, ask every patient about tobacco, advise quitting with a clear personalized message, assess readiness, assist with FDA-approved pharmacotherapy (varenicline or combination NRT first-line; bupropion as alternative) plus behavioral counseling, and arrange follow-up within one week of the quit date.

Board pearl: On Step 3, the right answer almost always pairs pharmacotherapy + counseling + structured follow-up — pick the option with all three, not the one that asks the patient to "try willpower" or "come back when ready."

Framework: 5 A's for ready quitters, 5 R's for the unready — never skip the conversation, never moralize, document every encounter

Pharmacotherapy: varenicline (most effective monotherapy, safe in stable CVD and psychiatric illness per EAGLES, renal-dose if CrCl <30), combination NRT (patch + lozenge/gum, comparable efficacy, OTC, first-line in pregnancy if counseling fails), bupropion (avoid in seizure or eating disorder, useful with comorbid depression) — combine pharmacotherapy with counseling for additive doubling of quit rates

Special populations: pregnancy = behavioral counseling first (Grade A), pharmacotherapy shared decision; hospitalized smokers = NRT on admission + cessation counseling + 1-week follow-up (Joint Commission measure); post-MI = initiate before discharge; clozapine/theophylline patients = anticipate level rise from CYP1A2 de-induction

Long-term: expect 5–7 quit attempts before success, treat lapses as learning opportunities not failures, extend pharmacotherapy beyond 12 weeks in high-risk patients, screen with LDCT in eligible smokers (age 50–80, ≥20 pack-years, quit <15 years), and continue to reinforce abstinence at every subsequent visit — because cardiovascular risk halves within one year and lung cancer mortality halves within ten years of quitting, making cessation the most cost-effective and life-extending intervention you will ever offer a patient